Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
AION Labs
AION Labs Overview
AION Labs is an alliance of AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund and Amazon Web Services (AWS) that have come together with one clear mission: to create and adopt new AI technologies that will transform the process of drug discovery and development in order to contribute to the health and well-being of all people world-wide.
Located within the Israeli biotech hotspot in Rehovot adjacent to Weizmann Institute for Sciences, AION Labs is a unique venture hub where brilliant innovators convene from around the world to solve the biggest R&D challenges guided by years of accumulated know-how, data and experience in pharma.
The lab leverages its partners wealth of knowledge and a new multidisciplinary mindset with the ingenuity, agility and innovative power of Israels start-up ecosystem, to develop strong companies with clear long-term strategies, that will pave the way to the future of healthcare. AION Labs cultivates innovation from within; its unique venture creation process bridges the gap between outstanding academic research in the field of AI and the biggest R&D needs in the discovery and development of new medicines for the benefit of patients.
The consortium is supported by the Israel Innovation Authority.
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
#Partners #Expand
May 2, 2022
nocamels.com
How AI And Machine Learning Are Transforming Drug Discovery and Development
#Investment #Acquisition #Partners
Feb 14, 2022
www.prnewswire.com
AION Labs, Powered by BioMed X, Launches Third Global Call for Application: Artificial Intelligence for Design and Optimization of Antibodies for Targeted Therapies
#Partners #Investment
Feb 13, 2022
www.prnewswire.com
AION Labs, Powered by BioMed X, Launches Second Global Call for Application: Artificial Intelligence for Clinical Trial Readiness of Drug Candidates
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
#Partners #Expand
May 2, 2022
nocamels.com
How AI And Machine Learning Are Transforming Drug Discovery and Development
#Investment #Acquisition #Partners
Feb 14, 2022
www.prnewswire.com
AION Labs, Powered by BioMed X, Launches Third Global Call for Application: Artificial Intelligence for Design and Optimization of Antibodies for Targeted Therapies
#Partners #Investment
Feb 13, 2022
www.prnewswire.com
AION Labs, Powered by BioMed X, Launches Second Global Call for Application: Artificial Intelligence for Clinical Trial Readiness of Drug Candidates